Abstract
Numerous cutaneous adverse effects (CAEs) have been reported with glucose-lowering medications (e.g. insulin, dipeptidyl peptidase 4 inhibitors and sulfonylureas) and medical devices (e.g. continuous subcutaneous insulin infusion and continuous glucose monitoring) used in the management of diabetes. Notable CAEs include angioedema, autoimmune blistering diseases, contact dermatitis, Stevens-Johnson syndrome and worsening blood glucose control. While some of CAEs are common and others rare, it is important for healthcare providers to be aware of the potential culprits and their associated CAEs, as well as effective methods to prevent and/or treat such effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
World Health Organization. Global report on diabetes. Geneva: WHO Press; 2016.
Rosen J, Yosipovitch G. Skin manifestations of diabetes mellitus. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2018.
Jedlowski PM, Te CH, Segal RJ, et al. Cutaneous adverse effects of diabetes mellitus medications and medical devices: a review. Am J Clin Dermatol. 2019;20(1):97–114.
Deng N, Zhang X, Zhao F, et al. Prevalence of lipohypertrophy in insulin-treated diabetes patients: a systematic review and meta-analysis. J Diabetes Investig. 2017. https://doi.org/10.1111/jdi.12742.
Al Ajlouni M, Abujbara M, Batieha A, et al. Prevalence of lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus. Int J Endocrinol Metab. 2015;13(2):e20776.
Gentile S, Strollo F, Della Corte T, et al. Insulin related lipodystrophic lesions and hypoglycemia: double standards? Diabetes Metab Syndr. 2018;12(5):813–8.
Renold AE, Winegrad AI, Martin DB. Diabetes mellitus and the adipose tissue [in French]. Helv Med Acta. 1957;24(4):322–7.
Rosenbloom AL. Insulin injection lipoatrophy recidivus. Pediatr Diabetes. 2014;15(1):73–4.
Kim D, Baraniuk J. Delayed-type hypersensitivity reaction to the meta-cresol component of insulin. Ann Allergy Asthma Immunol. 2007;99(2):194–5.
Gibbs JP, Fredrickson J, Barbee T, et al. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. J Clin Pharmacol. 2012;52(10):1494–505.
Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516–23.
Stricklin SM, Stoecker WV, Rader RK, et al. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®). Dermatol Online J. 2012;18(2):9.
Yaffee HS. Stevens–Johnson syndrome caused by chlorpropamide. Report of a case. Arch Dermatol. 1960;82:636–7.
Cheng JB, Anderson RC, Cruz PD Jr. Stevens–Johnson syndrome associated with glipizide therapy. Dermatitis. 2006;17(1):36–8.
Ernst EJ, Egge JA. Celecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy. 2002;22(5):637–40.
Ozuguz P, Kacar SD, Ozuguz U, et al. Erythroderma secondary to gliclazide: a case report. Cutan Ocul Toxicol. 2014;33(4):342–4.
Fisher AA. Systemic contact dermatitis from Orinase and Diabinese in diabetics with para-amino hypersensitivity. Cutis. 1982;29(6):551–6.
Contreras-Steyls M, Vilchez-Marquez F, Mota A, et al. Acute generalized exanthematous pustulosis induced by gliclazide: a case report. Int J Dermatol. 2013;52(12):1591–3.
Poszepczynska-Guigne E, Viguier M, Assier H, et al. Acute generalized exanthematous pustulosis induced by drugs with low-digestive absorption: acarbose and nystatin [in French]. Ann Dermatol Venereol. 2003;130(4):439–42.
Rigberg LA, Robinson MJ, Espiritu CR. Chlorpropamide-induced granulomas. A probable hypersensitivity reaction in liver and bone marrow. JAMA. 1976;235(4):409–10.
Bukhalo M, Zeitouni NC, Cheney RT. Leukocytoclastic vasculitis induced by use of glyburide: a case of possible cross-reaction of a sulfonamide and a sulfonylurea. Cutis. 2003;71(3):235–8.
Franz CB, Massullo RE, Welton WA. Lichenoid drug eruption from chlorpropamide and tolazamide. J Am Acad Dermatol. 1990;22(1):128–9.
Noakes R. Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride. Australas J Dermatol. 2003;44(4):302–3.
Hammami S, Ksouda K, Affes H, et al. Mucosal lichenoid drug reaction associated with glimepiride: a case report. Eur Rev Med Pharmacol Sci. 2015;19(12):2301–2.
Adams BB, Gadenne AS. Glipizide-induced pigmented purpuric dermatosis. J Am Acad Dermatol. 1999;41(5 Pt 2):827–9.
Rojas P, Sanchez L, Santos A, et al. Hypersensitivity to repaglinide. J Investig Allergol Clin Immunol. 2011;21(3):245–7.
Ross P, Gray AR, Milburn J, et al. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type. Acta Diabetol. 2016;53(6):991–8.
Pickup JC, Yemane N, Brackenridge A, et al. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabetes Technol Ther. 2014;16(3):145–9.
Berg AK, Olsen BS, Thyssen JP, et al. High frequencies of dermatological complications in children using insulin pumps or sensors. Pediatr Diabetes. 2018;19(4):733–40.
Author information
Authors and Affiliations
Consortia
Ethics declarations
Conflict of interest
The article was adapted from the American Journal of Clinical Dermatology 2019; 20(1): 97–114 by employees of Adis International Ltd./Springer Nature, who are responsible for the article content and declare no conflicts of interest.
Funding
The preparation of this review was not supported by any external funding.
Rights and permissions
About this article
Cite this article
Adis Medical Writers. Manage cutaneous adverse effects induced by diabetes medications or devices by removing the offending agent and choosing appropriate treatment. Drugs Ther Perspect 35, 557–562 (2019). https://doi.org/10.1007/s40267-019-00673-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-019-00673-1